Shasun Chemicals & Drugs Ltd has received the approval from Medicines and Healthcare products Regulatory Agency (MHRA), UK for its WHO - cGMP Formulation facility manufacturing Oral Solid Dosage forms (tablet and capsules) for the bulk tablets packing.
With this approval, the company's products from its brand new formulation facility could be sold on commercial basis to UK and European Countries, stated a release here.
Recently, Shasun had entered into a Letter of Intent with the Rhodia Group of France to acquire the pharmaceutical customs synthesis business of Rhodia Pharma Solutions (RPS).
Shasun has reported 43 per cent rise in net profit at Rs 12.90 crore for the third quarter ended December 2005 as compared to Rs 9.01 crore in the corresponding quarter previous year. Net sales grew by 33 per cent to Rs 98.41 crore as against Rs 73.88 crore during the same quarter previous year.